未知生产厂商
Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
Mosedipimod has been used in trials studying the supportive care and treatment of Chemotherapy-induced Neutropenia.
Mosedipimod is a proprietary compound originally derived from Sika deer antler. It accelerates endocytic trafficking of Pattern Recognition Receptors which allows for the swift removal of PAMPs/DAMPs. This drug has been shown to improve lung function and reduce inflammation and fibrosis in animal models. Currently, mosedipimod is being investigated against chemoradiation-induced oral mucositis and neutropenia, as well as against COVID-19.
